Is ALLR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% BioAtla N/A N/A -271.17%

Is BCAB or ATOS more profitable?

BioAtla's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -271.17% Atossa Genetics N/A -102.99% -85.78%

Is BCAB or NEUP more profitable?

BioAtla's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -271.17% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts recommend ALVR or BCAB?

BioAtla has a consensus target price of $200.00, suggesting a potential upside of 6,372.49%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, ALVR or BCAB?

BioAtla has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A BioAtla $8.50M 0.60 -$59.61M -$25.45 N/A

Is ALVR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% BioAtla N/A N/A -271.17%

Is CELU or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% BioAtla N/A N/A -271.17%

BioAtla (BCAB) Competitors

$3.09 -0.36 (-10.43%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.10 +0.01 (+0.16%)

As of 08/14/2026 07:34 PM Eastern

Compare

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

Should you buy BioAtla stock or one of its competitors? BioAtla's main competitors and comparable companies include Allarity Therapeutics (ALLR), Atossa Genetics (ATOS), Neuphoria Therapeutics (NEUP), AlloVir (ALVR), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioAtla compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
BioAtla	N/A	N/A	-271.17%

Allarity Therapeutics has higher earnings, but lower revenue than BioAtla. Allarity Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	68.11	-$11.23M	-$0.72	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

Allarity Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Allarity Therapeutics had 3 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for Allarity Therapeutics and 2 mentions for BioAtla. BioAtla's average media sentiment score of 2.44 beat Allarity Therapeutics' score of 0.97 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
BioAtla	Very Positive

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 648.18%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 6,372.49%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioAtla beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to Atossa Genetics?

BioAtla (NASDAQ:BCAB) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, BioAtla and BioAtla both had 2 articles in the media. BioAtla's average media sentiment score of 2.44 beat Atossa Genetics' score of 0.93 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Atossa Genetics	Positive

BioAtla has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Atossa Genetics has lower revenue, but higher earnings than BioAtla. Atossa Genetics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-271.17%
Atossa Genetics	N/A	-102.99%	-85.78%

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 6,372.49%. Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 682.05%. Given BioAtla's higher possible upside, equities research analysts clearly believe BioAtla is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atossa Genetics beats BioAtla on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to Neuphoria Therapeutics?

BioAtla (NASDAQ:BCAB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Neuphoria Therapeutics has higher revenue and earnings than BioAtla. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A
Neuphoria Therapeutics	$15.65M	1.34	-$370K	-$11.06	N/A

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 2 mentions for BioAtla. BioAtla's average media sentiment score of 2.44 beat Neuphoria Therapeutics' score of 0.37 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Neuphoria Therapeutics	Neutral

BioAtla has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 6,372.49%. Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 442.64%. Given BioAtla's higher possible upside, equities research analysts clearly believe BioAtla is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.2% of BioAtla shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.3% of BioAtla shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioAtla's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-271.17%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Summary

BioAtla beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to AlloVir?

AlloVir (NASDAQ:ALVR) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, BioAtla had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for BioAtla and 0 mentions for AlloVir. BioAtla's average media sentiment score of 2.44 beat AlloVir's score of 0.00 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
BioAtla	Very Positive

66.1% of AlloVir shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioAtla has a consensus target price of $200.00, suggesting a potential upside of 6,372.49%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

BioAtla's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
BioAtla	N/A	N/A	-271.17%

Summary

BioAtla beats AlloVir on 11 of the 14 factors compared between the two stocks.

How does BioAtla compare to Celularity?

Celularity (NASDAQ:CELU) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioAtla had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Celularity. BioAtla's average media sentiment score of 2.44 beat Celularity's score of 1.89 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Very Positive
BioAtla	Very Positive

BioAtla has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.76	-$91.72M	-$3.33	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 762.32%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 6,372.49%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Celularity has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

BioAtla has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
BioAtla	N/A	N/A	-271.17%

Summary

BioAtla beats Celularity on 8 of the 13 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.12M	$3.72B	$7.04B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.12	10.72	270.72	25.33
Price / Sales	0.60	1,230.44	574.42	74.73
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-0.11	16.78	12.92	6.25
Net Income	-$59.61M	-$13.32M	$3.45B	$347.82M
7 Day Performance	-10.69%	1.78%	1.16%	1.08%
1 Month Performance	-27.46%	1.17%	1.38%	0.82%
1 Year Performance	-83.19%	54.37%	62.53%	20.99%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	2.2696 of 5 stars	$3.09 -10.4%	$200.00 +6,372.5%	-83.0%	$5.12M	$8.50M	N/A	60	Positive News Earnings Report High Trading Volume
ALLR Allarity Therapeutics	2.7057 of 5 stars	$1.41 -0.1%	$10.25 +627.5%	+39.8%	$22.42M	$320K	N/A	10	News Coverage Earnings Report Gap Up
ATOS Atossa Genetics	2.6175 of 5 stars	$2.42 +1.9%	$20.33 +742.0%	-77.8%	$20.80M	N/A	N/A	8	News Coverage Earnings Report Analyst Upgrade
NEUP Neuphoria Therapeutics	2.3809 of 5 stars	$3.83 -0.8%	$21.00 +448.3%	-52.2%	$20.68M	$15.65M	N/A	N/A	Short Interest Increase
ALVR AlloVir	N/A	$4.07 -2.9%	N/A	+70.2%	$20.53M	N/A	N/A	110	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

How does BioAtla compare to Allarity Therapeutics?

Summary

How does BioAtla compare to Atossa Genetics?

Summary

How does BioAtla compare to Neuphoria Therapeutics?

Summary

How does BioAtla compare to AlloVir?

Summary

How does BioAtla compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

How does BioAtla compare to Allarity Therapeutics?

Do institutionals and insiders hold more shares of ALLR or BCAB?

Is ALLR or BCAB more profitable?

Which has stronger valuation and earnings, ALLR or BCAB?

Which has more volatility and risk, ALLR or BCAB?

Does the media favor ALLR or BCAB?

Do analysts recommend ALLR or BCAB?

Summary

How does BioAtla compare to Atossa Genetics?

Does the media prefer BCAB or ATOS?

Which has more risk & volatility, BCAB or ATOS?

Which has preferable earnings & valuation, BCAB or ATOS?

Do institutionals & insiders have more ownership in BCAB or ATOS?

Is BCAB or ATOS more profitable?

Do analysts recommend BCAB or ATOS?

Summary

How does BioAtla compare to Neuphoria Therapeutics?

Which has stronger earnings and valuation, BCAB or NEUP?

Does the media prefer BCAB or NEUP?

Which has more volatility & risk, BCAB or NEUP?

Do analysts recommend BCAB or NEUP?

Do institutionals & insiders believe in BCAB or NEUP?

Is BCAB or NEUP more profitable?

Summary

How does BioAtla compare to AlloVir?

Which has more volatility and risk, ALVR or BCAB?

Does the media favor ALVR or BCAB?

Do insiders and institutionals have more ownership in ALVR or BCAB?

Do analysts recommend ALVR or BCAB?

Which has better earnings and valuation, ALVR or BCAB?

Is ALVR or BCAB more profitable?

Summary

How does BioAtla compare to Celularity?

Do insiders & institutionals believe in CELU or BCAB?

Does the media favor CELU or BCAB?

Which has preferable earnings and valuation, CELU or BCAB?

Do analysts recommend CELU or BCAB?

Which has more volatility & risk, CELU or BCAB?

Is CELU or BCAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools